Table 3 Expression of EGFR, ERBB2, estrogen and progesterone receptors in human breast cancers identified as ERBB2-positive by immunohistochemistry

From: Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

 

Breast cancer subtypes

 

EGFR/ERBB2

ERBB2

Triple pos.

Total number

15

19

14

Relative number

31%

40%

29%

Age (years)

61.0

58.0

66.0

Number of lymph node metastasis

 0

3

13

7

 1

8

4

6

 2

3

0

0

 3

1

2

1

Lymph node metastasis negative tumors

3

13

7

Lymph node metastasis positive tumors

12

6

7

  1. Patients with breast cancers of the EGFR-high/ERBB2-positive subtype suffer more frequently of lymph node metastatis (P=0.0129).
Back to article page